Gemma Buck

Gemma Buck

Auto-generated profile, based on publicly available information

Gemma Buck

From the Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton, United Kingdom

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 March 2007 in Nature
Verified
Journal Article
Closed access
PDF file
CGChristopher Greenman
Christopher Greenman
PSPhilip Stephens
Philip Stephens
RSRaffaella Smith
Raffaella Smith
GDGillian L. Dalgliesh
Gillian L. Dalgliesh
CHChristopher Hunter
Christopher Hunter
MSMichael R. Stratton
Michael R. Stratton

6 January 2010 in Nature
Verified
Journal Article
Open access
PDF file
GDGillian L. Dalgliesh
Gillian L. Dalgliesh
KFKyle Furge
Kyle Furge
CGChris Greenman
Chris Greenman
LCLina Chen
Lina Chen
GBGraham Bignell
Graham Bignell
PFP. Andrew Futreal
P. Andrew Futreal
A large survey for somatic mutations in clear cell renal cell carcinomas, the most common form of adult kidney cancer, shows that in addition to the known inactivating mutations in the VHL gene, recurrent mutations occur in the NF2 gene, which encodes a tumour suppressor protein and in genes encoding the chromatin modifying enzymes SETD2, JARID1C and UTX. Clear cell renal carcinoma, the most common form of adult kidney cancer, is often characterized by the presence of inactivating mutations in the VHL gene. A large survey for somatic mutations now identifies inactivating mutations in two genes encoding enzymes involved in histone modification, highlighting the role of mutations in components of the chromatin modification machinery in human cancer. Clear cell renal cell carcinoma (ccRCC) is the most common form of adult kidney cancer, characterized by the presence of inactivating mutations in the VHL gene in most cases1,2, and by infrequent somatic mutations in known cancer genes. To determine further the genetics of ccRCC, we have sequenced 101 cases through 3,544 protein-coding genes. Here we report the identification of inactivating mutations in two genes encoding enzymes involved in histone modification—SETD2, a histone H3 lysine 36 methyltransferase, and JARID1C (also known as KDM5C), a histone H3 lysine 4 demethylase—as well as mutations in the histone H3 lysine 27 demethylase, UTX (KMD6A), that we recently reported3. The results highlight the role of mutations in components of the chromatin modification machinery in human cancer. Furthermore, NF2 mutations were found in non-VHL mutated ccRCC, and several other probable cancer genes were identified. These results indicate that substantial genetic heterogeneity exists in a cancer type dominated by mutations in a single gene, and that systematic screens will be key to fully determining the somatic genetic architecture of cancer.

11 July 2016 in Nature
Verified
Journal Article
Open access
PDF file
CFChristian Fuchsberger
Christian Fuchsberger
JFJason Flannick
Jason Flannick
TTTanya M. Teslovich
Tanya M. Teslovich
AMAnubha Mahajan
Anubha Mahajan
VAVineeta Agarwala
Vineeta Agarwala
MMMark I. McCarthy
Mark I. McCarthy
The genetic architecture of common traits, including the number, frequency, and effect sizes of inherited variants that contribute to individual risk, has been long debated. Genome-wide association studies have identified scores of common variants associated with type 2 diabetes, but in aggregate, these explain only a fraction of the heritability of this disease. Here, to test the hypothesis that lower-frequency variants explain much of the remainder, the GoT2D and T2D-GENES consortia performed whole-genome sequencing in 2,657 European individuals with and without diabetes, and exome sequencing in 12,940 individuals from five ancestry groups. To increase statistical power, we expanded the sample size via genotyping and imputation in a further 111,548 subjects. Variants associated with type 2 diabetes after sequencing were overwhelmingly common and most fell within regions previously identified by genome-wide association studies. Comprehensive enumeration of sequence variation is necessary to identify functional alleles that provide important clues to disease pathophysiology, but large-scale sequencing does not support the idea that lower-frequency variants have a major role in predisposition to type 2 diabetes.

29 March 2009 in Nature Genetics
Verified
Journal Article
Open access
PDF file
GHGijs van Haaften
Gijs van Haaften
GDGillian L Dalgliesh
Gillian L Dalgliesh
HDHelen Davies
Helen Davies
LCLina Chen
Lina Chen
GBGraham Bignell
Graham Bignell
PFP Andrew Futreal
P Andrew Futreal
Andrew Futreal and colleagues report inactivating somatic mutations in the histone lysine demethylase gene UTX in human cancers, including multiple myelomas, esophageal squamous carcinomas, renal clear cell carcinomas, acute and chronic myeloid leukemias, breast and colorectal cancers and glioblastomas, identifying UTX as a new tumor suppressor gene. Somatically acquired epigenetic changes are present in many cancers. Epigenetic regulation is maintained via post-translational modifications of core histones. Here, we describe inactivating somatic mutations in the histone lysine demethylase gene UTX, pointing to histone H3 lysine methylation deregulation in multiple tumor types. UTX reintroduction into cancer cells with inactivating UTX mutations resulted in slowing of proliferation and marked transcriptional changes. These data identify UTX as a new human cancer gene.

18 February 2010 in Nature
Verified
Journal Article
Open access
PDF file
GBGraham R. Bignell
Graham R. Bignell
CGChris D. Greenman
Chris D. Greenman
HDHelen Davies
Helen Davies
ABAdam P. Butler
Adam P. Butler
SESarah Edkins
Sarah Edkins
MSMichael R. Stratton
Michael R. Stratton
The cancer genome is moulded by the dual processes of somatic mutation and selection. Homozygous deletions in cancer genomes occur over recessive cancer genes, where they can confer selective growth advantage, and over fragile sites, where they are thought to reflect an increased local rate of DNA breakage. However, most homozygous deletions in cancer genomes are unexplained. Here we identified 2,428 somatic homozygous deletions in 746 cancer cell lines. These overlie 11% of protein-coding genes that, therefore, are not mandatory for survival of human cells. We derived structural signatures that distinguish between homozygous deletions over recessive cancer genes and fragile sites. Application to clusters of unexplained homozygous deletions suggests that many are in regions of inherent fragility, whereas a small subset overlies recessive cancer genes. The results illustrate how structural signatures can be used to distinguish between the influences of mutation and selection in cancer genomes. The extensive copy number, genotyping, sequence and expression data available for this large series of publicly available cancer cell lines renders them informative reagents for future studies of cancer biology and drug discovery.

19 April 2009 in Nature Genetics
Verified
Journal Article
Open access
PDF file
PTPatrick S Tarpey
Patrick S Tarpey
RSRaffaella Smith
Raffaella Smith
EPErin Pleasance
Erin Pleasance
AWAnnabel Whibley
Annabel Whibley
SESarah Edkins
Sarah Edkins
MSMichael R Stratton
Michael R Stratton
Tarpey et al. carry out a large-scale systematic sequencing of the majority of X-chromosome coding exons from 208 families with multiple individuals with mental retardation and a pattern of transmission compatible with X linkage in order to identify XLMR-causative mutations. They find several mutations that appear to be causative in loci already known to be involved in XLMR, as well as new data about those loci, and make inferences about the role of the different classes of variants in these diseases. Large-scale systematic resequencing has been proposed as the key future strategy for the discovery of rare, disease-causing sequence variants across the spectrum of human complex disease. We have sequenced the coding exons of the X chromosome in 208 families with X-linked mental retardation (XLMR), the largest direct screen for constitutional disease-causing mutations thus far reported. The screen has discovered nine genes implicated in XLMR, including SYP, ZNF711 and CASK reported here, confirming the power of this strategy. The study has, however, also highlighted issues confronting whole-genome sequencing screens, including the observation that loss of function of 1% or more of X-chromosome genes is compatible with apparently normal existence.